Novartis presented positive results from the pivotal phase III ASC4FIRST trial as a late-breaking abstract at the 2024 American Society of Clinical Oncology meeting.Â
Novartis presented positive primary endpoint data from the phase III NATALEE trial at the 2023 American Society of Clinical Oncology Annual Meeting.Â
An ongoing phase I/II study evaluating Regeneron Pharmaceuticals’ first-in-class costimulatory bispecific antibody, REGN7075 (EGFRxCD28), in combination with Libtayo (cemiplimab) in patients with advanced solid tumors showed positive new results.Â
Iovance Biotherapeutics Inc. a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, has updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting.Â
A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone. The work will be presented at the 2024 ASCO Annual Meeting.Â
Topline overall survival results from the TROPION-Lung01 phase III trial, which previously met the dual primary endpoint of progression-free survival, numerically favored datopotamab deruxtecan compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior line of therapy.Â
A new study examines the cost-effectiveness of durvalumab, a targeted immunotherapy for lung cancer that is known to extend lifespan.Â
The Association of Cancer Care Centers and LUNGevity have launched the Electronic Health Records Integrations for Biomarker Testing: Roadmap, a new virtual resource to support multidisciplinary cancer care teams prepare, implement, and evaluate electronic health record integrations for biomarker testing.
Researchers at UT Southwestern Medical Center have developed a novel artificial intelligence model to improve the detection of breast cancer metastasis, which could reduce the need for needle or surgical biopsies.
Orca Bio will present new data at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.Â
